HU0300696A3 - Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha - Google Patents

Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha

Info

Publication number
HU0300696A3
HU0300696A3 HU0300696A HU0300696A HU0300696A3 HU 0300696 A3 HU0300696 A3 HU 0300696A3 HU 0300696 A HU0300696 A HU 0300696A HU 0300696 A HU0300696 A HU 0300696A HU 0300696 A3 HU0300696 A3 HU 0300696A3
Authority
HU
Hungary
Prior art keywords
nhha
proteins
surface antigen
neisseria meningitidis
conserved regions
Prior art date
Application number
HU0300696A
Other versions
HU0300696A2 (en
Original Assignee
Univ Queensland Brisbane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US17791700P priority Critical
Application filed by Univ Queensland Brisbane filed Critical Univ Queensland Brisbane
Priority to PCT/AU2001/000069 priority patent/WO2001055182A1/en
Publication of HU0300696A2 publication Critical patent/HU0300696A2/en
Publication of HU0300696A3 publication Critical patent/HU0300696A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
HU0300696A 2000-01-25 2001-01-25 Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha HU0300696A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17791700P true 2000-01-25 2000-01-25
PCT/AU2001/000069 WO2001055182A1 (en) 2000-01-25 2001-01-25 PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA

Publications (2)

Publication Number Publication Date
HU0300696A2 HU0300696A2 (en) 2003-07-28
HU0300696A3 true HU0300696A3 (en) 2004-10-28

Family

ID=22650445

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300696A HU0300696A3 (en) 2000-01-25 2001-01-25 Proteins comprising conserved regions of neisseria meningitidis surface antigen nhha

Country Status (17)

Country Link
US (4) US7947291B2 (en)
EP (2) EP1252182B1 (en)
JP (3) JP2003523208A (en)
CN (2) CN1419564A (en)
AU (1) AU2818101A (en)
BR (1) BR0107857A (en)
CA (1) CA2398139A1 (en)
CZ (1) CZ304379B6 (en)
ES (1) ES2389719T3 (en)
HU (1) HU0300696A3 (en)
IL (2) IL150822D0 (en)
MX (1) MXPA02007184A (en)
NO (1) NO332229B1 (en)
NZ (1) NZ520445A (en)
PL (1) PL216780B1 (en)
WO (1) WO2001055182A1 (en)
ZA (1) ZA200206153B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333071T5 (en) * 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Neisseria meningitidis antigens
MX343744B (en) 1998-05-01 2016-11-22 J Craig Venter Inst Inc Neisseria meningitidis antigens and compositions.
DK1228217T3 (en) * 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Preserved Neisseria Antigens
EP2270173B1 (en) * 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP1252182B1 (en) * 2000-01-25 2012-06-20 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
ES2281409T3 (en) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Neisseria protein heterology expression.
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
ES2575014T3 (en) 2002-08-02 2016-06-23 Glaxosmithkline Biologicals S.A. Neisseria vaccine compositions comprising a combination of antigens
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
WO2007042326A2 (en) * 2005-10-14 2007-04-19 Intercell Ag Neisseria meningitidis antigens
DE602007003596D1 (en) 2006-06-12 2010-01-14 Glaxosmithkline Biolog Sa Vaccine
JP2012512240A (en) 2008-12-17 2012-05-31 ノバルティス アーゲー Meningococcal vaccine containing hemoglobin receptor
CN102438649A (en) 2009-03-24 2012-05-02 诺华有限公司 Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
BR112012004275A2 (en) 2009-08-27 2016-11-16 Novartis Ag hybrid polypeptides including meningococcal fhbp sequences
CA2772103A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
BR112012010531A2 (en) 2009-10-27 2019-09-24 Novartis Ag "fhbp meningococcal modification polypeptides"
JP2013521326A (en) 2010-03-10 2013-06-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
WO2011110655A2 (en) 2010-03-11 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
CA2806613A1 (en) * 2010-07-30 2012-02-02 Griffith University Recombinant neisseria meningitidis pora porin proteins
EP2613805B1 (en) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
BR112014016223A8 (en) 2011-12-29 2017-07-04 Novartis Ag adjuvant combinations of meningococcal h-factor binding proteins
AU2013214105A1 (en) 2012-02-02 2014-07-24 Novartis Ag Promoters for increased protein expression in meningococcus
JP2015517089A (en) 2012-03-08 2015-06-18 ノバルティス アーゲー In vitro efficacy assay for protein-based meningococcal vaccines
JP2015521595A (en) 2012-06-14 2015-07-30 ノバルティス アーゲー Vaccine for serogroup X meningococcus
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
BE1025443B1 (en) 2016-11-25 2019-02-28 Glaxosmithkline Biologicals Sa Nomv-antigen conjugates and their use
EP3544625A2 (en) 2016-11-25 2019-10-02 GlaxoSmithKline Biologicals S.A. Immunogenic conjugates and use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4550081A (en) 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4366241B1 (en) 1980-08-07 1988-10-18
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0273116A3 (en) * 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
JPH03504157A (en) 1988-03-24 1991-09-12
ES2070312T5 (en) * 1988-12-19 2003-05-16 American Cyanamid Co Class 1 meningococic external membrane protein vaccine.
AU649066B2 (en) 1990-07-25 1994-05-12 Syngene, Inc. Circular extension for generating multiple nucleic acid complements
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5646259A (en) 1995-03-24 1997-07-08 St. Louis University DNA encoding haemophilus adhesion proteins
EP0862656B1 (en) 1995-11-21 2001-03-07 Yale University Unimolecular segment amplification and detection
GB9611673D0 (en) * 1996-06-05 1996-08-07 Peptide Therapeutics Ltd Meningococcal vaccine
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
ES2333071T5 (en) * 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Neisseria meningitidis antigens
MX343744B (en) 1998-05-01 2016-11-22 J Craig Venter Inst Inc Neisseria meningitidis antigens and compositions.
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
EP1185691B1 (en) * 1999-04-30 2009-04-29 Novartis Vaccines and Diagnostics, Inc. Neisseria genomic sequences and methods of their use
WO2000061165A1 (en) 1999-04-13 2000-10-19 Smithkline Beecham Corporation Conserved adhesin motif and methods of use thereof
DK1228217T3 (en) * 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Preserved Neisseria Antigens
GB9916529D0 (en) * 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP1252182B1 (en) 2000-01-25 2012-06-20 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
ES2575014T3 (en) * 2002-08-02 2016-06-23 Glaxosmithkline Biologicals S.A. Neisseria vaccine compositions comprising a combination of antigens
CA2550927A1 (en) * 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection

Also Published As

Publication number Publication date
CN1419564A (en) 2003-05-21
CZ20022482A3 (en) 2003-01-15
NZ520445A (en) 2004-02-27
CA2398139A1 (en) 2001-08-02
PL216780B1 (en) 2014-05-30
BR0107857A (en) 2002-10-29
US20130136762A1 (en) 2013-05-30
JP2003523208A (en) 2003-08-05
CN102417537A (en) 2012-04-18
US8383790B2 (en) 2013-02-26
EP2395013A3 (en) 2012-03-21
JP2012051902A (en) 2012-03-15
EP1252182A1 (en) 2002-10-30
JP2014024849A (en) 2014-02-06
US8367070B2 (en) 2013-02-05
EP2395013A2 (en) 2011-12-14
EP1252182A4 (en) 2005-03-02
WO2001055182A1 (en) 2001-08-02
US20090068229A1 (en) 2009-03-12
AU2818101A (en) 2001-08-07
CZ304379B6 (en) 2014-04-09
US20020160016A1 (en) 2002-10-31
PL356819A1 (en) 2004-07-12
MXPA02007184A (en) 2004-02-26
IL150822A (en) 2011-06-30
EP1252182B1 (en) 2012-06-20
ZA200206153B (en) 2003-11-03
US20090068216A1 (en) 2009-03-12
HU0300696A2 (en) 2003-07-28
NO20023487D0 (en) 2002-07-22
NO332229B1 (en) 2012-08-06
ES2389719T3 (en) 2012-10-30
US7947291B2 (en) 2011-05-24
NO20023487L (en) 2002-09-24
IL150822D0 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
DK1946769T3 (en) Multivalent reduced dose vaccine composition of Haemophilus influenzae type B
DK1253883T3 (en) Apparatus for the treatment of heartburn and reflux disease
DE60123583D1 (en) Dehydratisation / rehydratisation process for the preparation of liposome
DE50114754D1 (en) Enossal dental implant
DK1947187T5 (en) Hybrid Expression of Neisserial proteins
DK1228728T3 (en) sleeping Facilities
DE60127333D1 (en) spinal implant
DE60239067D1 (en) Preparation of display changes
DE60232893D1 (en) Eddy implant
DE50109784D1 (en) Stabilized protein preparation and process for its preparation
DE69941567D1 (en) Antigene from neisseria meningitidis
FR2814058B1 (en) Set of implants and corresponding implants
DE60136623D1 (en) Modification of protein lyolation in pichia pastoris
DE50103504D1 (en) Process for the preparation of dialkoxythiophenes and alkylenedioxythiophenes
DE60118805D1 (en) Process for the preparation of silicone emulsions
DE60142689D1 (en) Use of procariotic pest-similar peptides for increasing the immunogenicity of antigens
DK1524993T3 (en) Neisseria vaccine composition comprising a combination of antigens
DK1389920T3 (en) Preparation of oilseed protein isolate
DE60144277D1 (en) Hemmer of human phosphatidyl-inositol-3-kinase delta
DE60143535D1 (en) Human antibodies against cd40
DE50109676D1 (en) Shoehorn prosthesis
DE60108594D1 (en) Massage chair
DK1409539T3 (en) Process for Preparation of a Protein Containing Enriched Beta-TGF in Activated Form, Protein Fraction and Therapeutic Uses
HK1065471A1 (en) Methods of administering anti-tnf-alpha antibodies
DE60105843D1 (en) walker

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished